Arcus Biosciences, Inc. (RCUS) News
Track canonical SquawkNews coverage tagged to RCUS, Arcus Biosciences, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
RCUS - Arcus Biosciences Announces New Employment Inducement Grants
RCUS - Arcus Biosciences Announces New Employment Inducement Grants
EQUITY | Aug 11, 2026, 08:36 PM UTC
L
RCUS - Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
RCUS - Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
EQUITY | Aug 05, 2026, 08:18 PM UTC
L
RCUS PT raised from $32 to $45, maintains Buy @ HCW
RCUS PT raised from $32 to $45, maintains Buy @ HCW
EQUITY | Jul 20, 2026, 01:14 PM UTC
L
Arcus Biosciences Insider Sold Shares Worth $2,031,919, According to a Recent SEC Filing
() -- Juan C. Jaen, President, on July 09, 2026, sold 68,569 shares in Arcus Biosciences (RCUS) for $2,031,919. Following the Form 4 filing with the SEC, Jaen has control over a total of 1,200,531 common shares of the co
GEOPOLITICS | Jul 13, 2026, 09:44 PM UTC
L
Arcus Biosciences Announces Publication In Nature Describing New Research From The ARC-20 Study Showing Casdatifan HIF-2a Inhibition Deeply
This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology HIF-2a inhibition with casdatifan result
EQUITY | Jul 01, 2026, 03:02 PM UTC